glucocorticoid by binding to the glucocorticoid receptor (GR), a ligand-activated nuclear receptor that regulates a wide range of genes involved in energy metabolism and inflammation [3] . This enzyme is highly expressed in liver and adipose tissue, where it may increase the intracellular active form of glucocorticoid, and has a critical role in the pathogenesis of visceral obesity and insulin resistance [1, [4] [5] [6] [7] [8] . Transgenic mice overexpressing Hsd11b1 develop obesity, insulin resistance, dyslipidemia, and diabetes [9] . Conversely, inhibition or a lack of Hsd11b1, such as in Hsd11b1 null mice, manifests as improvements in lipid profile, hepatic insulin sensitivity, and glucose tolerance [10] [11] [12] [13] .
Hexose-6-phosphate dehydrogenase (H6PD) is an important factor in determining the redox state of control subjects were ≥60 years of age and had no history of diabetes, no first-degree relatives with diabetes, FPG concentration <100 mg/dL, and glycated hemoglobin (hemoglobin A1c, HbA1c) ≤5.7%.
Subjects were classified as having metabolic syndrome if they had any three of the following five characteristics: central obesity (waist circumference >90 cm in males or >80 cm in females), hypertriglyceridemia (triglycerides ≥150 mg/dL or triglyceride-lowering medication), high density lipoprotein cholesterol (HDL-C; <40 mg/dL in males or <50mg/dL in females), hypertension (≥130 mmHg systolic or ≥85 mmHg diastolic pressure, or use of anti-hypertensive medication), hyperglycemia (FPG ≥100 mg/dL or use of anti-hyperglycemic medication, or previously diagnosed type 2 diabetes) [23, 24] .
The Institutional Review Board of Kyungpook National University Hospital approved the study protocol. All participants agreed to participate in the Korean Genomic Cohort Study and gave written informed consent for the investigation, including genetic analysis.
The subjects underwent evaluation using a questionnaire, physical examination, and laboratory tests. In physical examinations, waist circumference, height, body weight, and blood pressure were measured by standard methods. Waist circumference was measured at the narrowest point of the waist as viewed from the front. Prior to measuring blood pressure, the subjects were asked to rest for 10 minutes and, while seated, the systolic and diastolic pressures in the upper arm were measured twice.
Laboratory analysis
Blood was drawn from all patients in the morning after an overnight fast. Fasting blood glucose levels were measured by the hexokinase method using a Modular Analytics SWA apparatus (Roche Diagnostics GmbH, Mannheim, Germany). HbA1C levels were measured by high performance liquid chromatography using a VARIANT II apparatus (Bio-Rad Laboratories, Hercules, CA, USA). Total serum cholesterol levels were measured by an enzymatic calorimetric test. Triglyceride levels were measured by an enzymatic assay without a glycerol blank. HDL and low density lipoprotein (LDL) levels were measured by an enzymatic selective protection assay. Blood urea nitrogen (BUN) and creatinine levels were measured by a ureasewith-GLDH (glutamate dehydrogenase) assay and the kinetic colorimetric Jaffe method, respectively. Total the endoplasmic reticulum lumen. H6PD functions by producing NADPH, which HSD11B1 requires as a cofactor to maintain its reductase activity [14, 15] . Thus, H6PD supplies NADPH, which is crucial for the ability of HSD11B1 to amplify intracellular cortisol. Reduction of H6pd expression ameliorates diet-induced obesity and insulin resistance in mice [16] .
Polymorphisms of HSD11B1 were reported to be associated with type 2 diabetes and insulin resistance in Pima Indians [17] . However, several other studies have failed to find evidence of an association between HSD11B1 polymorphisms and type 2 diabetes, obesity, or metabolic syndrome [18] [19] [20] [21] .
To our knowledge, there has been no study designed to specifically evaluate the relationship of H6PD polymorphisms with metabolic syndrome or diabetes. Moreover, few studies have examined the collective effects of single nucleotide polymorphisms (SNPs) in HSD11B1 and H6PD on type 2 diabetes or metabolic syndrome.
In this study, we examined the role of common polymorphisms of HSD11B1 [IVS3-29G/T (rs12086634) and IVS4-11120A/G (rs1000283)] and H6PD [R453Q (rs6688832) and P554L (rs17368528)], individually and in combination, on type 2 diabetes and metabolic syndrome in a Korean population.
Materials and Methods

Study subjects
A total of 785 subjects were enrolled in this study: 427 unrelated patients with type 2 diabetes registered at the Diabetes Clinic of the Kyungpook National University Hospital from April, 2006 to October, 2010, and 358 nondiabetic control subjects in Ulchin and Dalsung Counties, Korea. All subjects enrolled in this study were of Korean ethnicity. The individual calculated statistical powers were 84.0% (rs12086634), 80.7% (rs1000283), 81.6% (rs6688832), and 70.8% (rs17368528) with a type 1 error of 0.05, assuming that a high risk allele frequency was 0.227, 0.171, 0.378, and 0.088, respectively, and that the relative risk of a dominant genotype was 1.4. We referred to data of risk allele frequency in the Asian population that is contained in the international HapMap project (http:// www.hapmap.org/) [22] .
Subjects were defined as having type 2 diabetes if they had a history of type 2 diabetes, fasting plasma glucose (FPG) concentrations ≥126 mg/dL, or 2 h postprandial serum glucose ≥200 mg/dL. Non-diabetic in each group) was evaluated using Student's t-test. The categorical variables of the groups were compared by Chi-square analysis. The Chi-square test was also used to determine whether individual polymorphisms were in Hardy-Weinberg equilibrium. Logistic regression analysis adjusted for age, gender, smoking, alcohol consumption, and serum creatinine levels was used to determine individual and combined gene effects. To test the combined effects of the genes on type 2 diabetes and metabolic syndrome, we introduced an interaction term to the logistic regression model. Genotypes were encoded as 0, 1, and 2 for additive; 0, 1, and 1 for dominant; and 0, 0, and 1 for recessive. Odds ratios (OR) and 95% confidence intervals (CI) were also calculated. Associations between SNPs and metabolic parameters were analyzed in the study population using multiple linear regression adjusted for age and gender. The association between HSD11B1 and H6PD haplotype and type 2 diabetes was assessed by the Chi-square test using Haploview software (http://www.broad.mit.edu/mpg/haploview/). Analysis was performed using SPSS 15.0 (SPSS, Chicago, IL, USA). P <0.05 was considered significant.
results
Baseline characteristics of the study population
Clinical and metabolic characteristics of the control and type 2 diabetes groups are shown in Table 1 . Mean ages of the control (n=358) and type 2 diabetes groups (n=427) were 66.8 ± 0.3 and 57.5 ± 0.6 years, respectively (P<0.05). The type 2 diabetes group had higher mean waist circumference, triglyceride, FPG, HbA1C, and BUN values than the control group (P <0.05). Male gender and use of anti-hypertensive and lipid-lowering drugs were all more prevalent among type 2 diabetics than among controls (P<0.05). Systolic blood pressure, total cholesterol, HDL-C, and prevalence of alcohol use were higher in the control group than in the type 2 diabetes group (P<0.05).
Association of polymorphisms with type 2 diabetes
All genotype frequencies in each group were in Hardy-Weinberg equilibrium (P > 0.05) ( Table 2) . No significant association was found between the SNPs studied and type 2 diabetes. Although there was a trend towards a lower frequency of the AA genotype for HSD11B1 rs1000283 among type 2 diabetics (OR= 0.206, 95%CI 0.043-0.976, P=0.046), significance was not maintained after adjusting for age, gender, and cholesterol, triglyceride, HDL, LDL, BUN, and creatinine levels were determined using a Hitachi Modular Analytics D2400 apparatus (Roche, Tokyo, Japan).
DNA extraction and genotyping
Genomic DNA was isolated from participants' whole blood using the Puregene DNA Isolation kit (Qiagen, Valencia, CA, USA) according to the manufacturer's instructions [25] . Two SNPs in the HSD11B1 gene [IVS3-29G/T (rs12086634) in intron 3 and IVS4-11120A/G (rs1000283) in intron 5] and two SNPs in the H6PD gene [R453Q (rs6688832) and P554L (rs17368528) in exon 5] were analyzed. We selected these four SNPs after consulting previously published studies suggesting a positive association of these SNPs with metabolic disease [17, 26, 27] and reviewing the allele frequencies of the Asian population and locations using the international HapMap project (http://www.hapmap.org/). LD coefficient r 2 between rs12086634 and rs1000283, and rs6688832 and rs17368528 were 0.00 and 0.62 respectively (http://www.broad.mit.edu/mpg/haploview/).
Genotype screening of rs12086634 was accomplished using a single base primer extension assay (ABI PRISM SNaPShot Multiplex kit; Applied Biosystems, Foster City, CA, USA) according to the manufacturer's instructions. Analysis was carried out using Genemapper software (version 4.0; Applied Biosystems). Genotyping of the HSD11B1 polymorphism rs1000283 and H6PD polymorphisms rs6688832 and rs17368528 was performed using the TaqMan fluorogenic 5' nuclease assay (Applied Biosystems). All polymerase chain reactions (PCRs) were performed using 384-well plates on a Dual 384-Well GeneAmp PCR System 9700 (Applied Biosystems) and endpoint fluorescence readings were performed with an ABI PRISM 7900 HT Sequence Detection System (Applied Biosystems). Duplicate samples and negative controls were included to ensure accuracy of genotyping. Genotyping methods and primer and probe sequences are included in Supplementary Table 1. All genotyping was performed using DNA LINK (Seoul, Korea).
Statistical analyses
Nominal variables were presented as the number and percentage of cases and continuous variables as means ± standard error. The significance of the mean differences between the two groups (patients with type 2 diabetes vs. nondiabetic control, and patients with metabolic syndrome vs. those without metabolic syndrome The prevalence of the HSD11B1 rs12086634 GT + GG genotype was significantly lower than that of TT homozygotes among subjects with metabolic syndrome (GT/GG vs. TT; OR 0.556, 95% CI 0.367-0.843, P=0.005, Bonferroni corrected P= 0.020) and the prevalence of the HSD11B1 rs1000283 GA + AA genotype was significantly lower than that of GG homozygotes among subjects with metabolic syndrome (GA/ AA vs. GG; OR 0.541, 95% CI 0.343-0.854, P=0.008, Bonferroni corrected P=0.032). This significance was maintained after adjusting for age, gender, smoking status, alcohol consumption, and serum creatinine levels (Bonferroni corrected P=0.028 and P=0.016, respectively). By contrast, the SNPs in H6PD, rs6688832 and rs17368528 showed no significant association with metabolic syndrome (Table 3) .
Association of polymorphisms with metabolic syndrome in non-diabetic patients
The mean ages of non-diabetic subjects with (n=82) and without metabolic syndrome (n=276) were 65.1 ± body mass index (OR=0.280, 95% CI 0.055-1.434, P=0.127). The AA genotype for H6PD rs6688832 also showed a lower frequency among type 2 diabetics in logistic regression analysis adjusted for age, gender, and body mass index (OR=0.674, 95% CI 0.461-0.983, P=0.041) ( Table 2 ). However, after considering multiple comparisons, the P value was not statistically significant (Bonferroni corrected P=0.164). No evidence was found for a combined effect of HSD11B1 and H6PD on type 2 diabetes or metabolic syndrome (data not shown). Haplotypes of polymorphisms of HSD11B1 and H6PD were not associated with type 2 diabetes (Supplementary Table 2 ).
Association of polymorphisms with metabolic syndrome in diabetic patients
The basal characteristics of patients with and without metabolic syndrome are summarized in Supplementary  Table 3 . The HSD11B1 SNPs rs12086634 and rs1000283 showed significant associations with metabolic syndrome (P=0.016 and P=0.006, respectively). rs6688832) polymorphisms are not significantly related to the risk of type 2 diabetes and metabolic syndrome and that there is no combined effect of these polymorphisms on the risk of type 2 diabetes or metabolic syndrome, although these negative associations could not be confirmed because of insufficient statistical power in this study due to sample size.
Recently, HSD11B1 has emerged as a promising therapeutic target for diabetes and obesity [28] [29] [30] [31] . HSD11B1, which amplifies intracellular glucocorticoid activity, plays a critical role in the pathogenesis of visceral obesity, metabolic syndrome, and diabetes [1, 4-8]. H6PD, which uses glucose-6-phosphate (G6P) to reduce coenzyme NADP + to NADPH, is a crucial determinant of the fate of HSD11B1 as an oxoreductase [14] .
HSD11B1 and H6PD are encoded by the chromosomal regions 1q32-q41 and 1p36, respectively. Polymorphisms of HSD11B1 (rs846910 and rs12086634) have been associated with the risk of type 2 diabetes in Pima Indians [17] . In that previous study, individuals with the TT genotype of the HSD11B1 rs12086634 polymorphism had a higher risk of diabetes than those with the GG+GT genotype (OR1.79, 95%CI 1.14-2.8, P=0.01). However, our study did not show a significant effect of genotype for this polymorphism (P=0.997), even though Pima Indians originated in Asia and may be somewhat genetically similar to Koreans. Instead, the present data indicated that the HSD11B1 rs12086634 polymorphism was associated with metabolic syndrome in type 2 diabetes. Combination of polymorphisms of HSD11B1 (rs846910 and rs12086634) was reported to associate with metabolic syndrome regardless of the diagnosis of polycystic ovary syndrome [32] and an association of HSD11B1 g.-19835A (rs846908) or g.-19609G (rs701950) with higher FPG and body mass index was observed [20] .
However, HSD11B1 polymorphisms were not previously associated with susceptibility to type 2 diabetes in Koreans [20] . The prevalence of HSD11B1 +9410T>A (rs2236905), +17925C>T(rs2298930), and +27447G>C(rs932335) was found to be not significantly different among subjects with metabolic syndrome and controls without any metabolic syndrome components in a Japanese population [21] .
The H6PD R453Q variant has been associated with polycystic ovarian syndrome [27] . However, another study showed no evidence that the combined effects 0.5 and 67.3 ± 0.3 years, respectively (P<0.05). Basal characteristics of patients with and without metabolic syndrome are presented in Supplementary Table 3 . The SNP in H6PD rs17368528 showed a significant association with metabolic syndrome (P=0.022). The H6PD rs17368528 CT + TT genotype was more prevalent than the CC homozygote genotype among metabolic syndrome subjects after adjusting for age, gender, smoking status, alcohol consumption, and creatinine (CT/TT vs. CC; OR 4.717, 95% CI 1.489-14.942, P=0.008, Bonferroni corrected P=0.032) ( Table 3) . Other polymorphisms (H6PD rs6688832, HSD11B1 rs12086634, and rs1000283) showed no association with metabolic syndrome.
Association of polymorphisms with metabolic syndrome in the total subjects
In the total study population including subjects with type 2 diabetes and those without, the prevalence of the HSD11B1 rs1000283 GA + AA genotype was significantly lower than that of GG homozygotes among subjects with metabolic syndrome (GA/AA vs. GG; OR 0.708, 95% CI 0.508-0.988, P=0.043) and the H6PD rs17368528 CT + TT genotype was more prevalent than the CC homozygote genotype among metabolic syndrome subjects after adjusting for age, gender, smoking status, alcohol consumption, and creatinine (CT/ TT vs. CC; OR 1.828, 95% CI 1.031-3.241, P=0.039). However, the significance was not maintained after considering multiple comparisons (Table 3) .
Association of clinical parameters With HSD11B1 polymorphism and H6PD polymorphism genotypes
Multiple linear regression analysis adjusted for age and gender showed that the HSD11B1 polymorphism rs12086634 was significantly associated with diastolic blood pressure in subjects with type 2 diabetes and the total study population (P=0.040 and P=0.014 respectively). HDL-C was higher among H6PD polymorphism rs17368528 CC homozygotes than among those with the CT + TT genotype in control and the total study population (P=0.010 and P=0.014 respectively). Other metabolic syndrome parameters were not significantly different between genotypes (Table 4) .
discussion
This study revealed that the HSD11B1 (rs12086634 and rs1000283) and the H6PD (rs17368528 and rs1000283 and the H6PD polymorphism rs17368528 were associated with metabolic syndrome after adjusting for confounding variables. However, this significance disappeared after considering multiple comparisons.
In contrast, the HSD11B1 polymorphisms rs12086634 and rs1000283 were associated with metabolic syndrome in type 2 diabetics, and the H6PD polymorphism rs17368528 was a risk factor for metabolic syndrome in subjects who do not have type 2 diabetes. This significance was maintained after adjusting for age, gender, smoking status, alcohol consumption, and serum creatinine levels and after taking multiple comparisons into account. It is unclear why this discrepancy exists in the association of the SNPs and metabolic syndrome between subjects with type 2 diabetes and those without type 2 diabetes; possible explanations include the small study sample size or different susceptibility to metabolic syndrome between subjects with and without type 2 diabetes. Because this study was not designed of two SNPs in HSD11B1 (83,557insA) and H6PD (R453Q, rs6688832) were associated with body composition including weight, height, body mass index, waist circumference, blood pressure, or glucose metabolism, as assessed by a nonfasting glucose tolerance test in nondiabetic subjects [18] .
Although previous studies of these two enzymes have been somewhat inconsistent, the mechanisms of action of HSD11B1 and H6PD are widely believed to be critical for the pathogenesis of metabolic syndrome and diabetes. The inconsistency of previous studies may be at least partly due to differences in study populations, study design, and loci of polymorphisms studied.
Our study suggests that the HSD11B1 (rs12086634 and rs1000283) and the H6PD (rs17368528 and rs6688832) polymorphisms are not associated with type 2 diabetes and metabolic syndrome. In the total study population, which included subjects with type 2 diabetes and those without, the HSD11B1 polymorphism effect of the polymorphisms on metabolic syndrome in the subgroups could not be determined. Further studies are needed to confirm these results.
In conclusion, there was no significant association of common SNPs in HSD11B1 (rs12086634, rs1000283) and H6PD (rs6688832, rs17368528), either separately or combined, with type 2 diabetes and metabolic syndrome. Therefore, these polymorphisms may not be associated with type 2 diabetes and metabolic syndrome. However, it is still possible that these polymorphisms affect metabolic syndrome phenotypes. Further investigation is required to verify these results as well as to provide functional analysis of the effects of these genetic variations on the pathogenesis of metabolic syndrome.
to specifically examine the association of these polymorphisms with metabolic syndrome among subjects with type 2 diabetes or without, we could not confirm a positive association of these polymorphisms with metabolic syndrome in these groups.
Specifically, HDL-C and diastolic blood pressure were significantly associated with the H6PD polymorphism rs17368528 and the HSD11B1 polymorphism rs12086634, respectively. Despite this finding, other metabolic parameters were not significantly different between genotypes. Whether these HSD11B1 and H6PD polymorphisms are related to a certain component of metabolic syndrome should be investigated in further studies.
This study has several limitations. First, there were significant differences in the gender ratios and the distribution of ages between the control and diabetic subjects, which may constitute a selection bias. However, regression analysis was performed after controlling for these variables. Second, the entire gene was not sequenced to identify SNPs for screening. Although 4 SNPs were selected after reviewing the allele frequency in the Asian population and consulting previously published studies, other SNPs may also have strong associations with diabetes or metabolic syndrome in Asians. Third, this study utilized a sample size with insufficient statistical power to detect a negative association between the SNP (rs17368528) and type 2 diabetes although other SNPs have sufficient statistical powers. Thus, the possibility of a positive association between these SNPs and diabetes still remains. Finally, functional analyses of the polymorphisms were not performed, and so a causal 
